Abstract
Numerous studies have demonstrated a critical role for the c-myc gene in the control of cellular growth. Alterations of the c-myc gene have been found associated with many different types of tumors in several species, including humans. The increased synthesis of one of the major forms of c-Myc protein, c-Myc 1, upon methionine deprivation provides a link between the regulation of oncogenes and the nutritional status of the cell. While deregulation or overexpression of the other major form, c-Myc 2, has been shown to cause tumorigenesis, the synthesis of c-Myc 1 protein is lost in many tumors. This suggests that the c-Myc 1 protein is necessary to keep the c-Myc 2 protein “in check” and prevent certain cells from becoming tumorigenic. Indeed, we have shown that overproduction of c-Myc 1 can inhibit cell growth. We have also shown that c-Myc 1 and 2 proteins have a differential molecular function in the regulation of transcription through a new binding site for Myc/Max heterodimers. We have also recently identified new translational forms of the c-Myc protein which we term Δ-c-Myc. These proteins arise from translational initiation at downstream start sites which yield N-terminally-truncated c-Myc proteins. Since these proteins lack a significant portion of the transactivation domain of c-Myc, they behave as dominant-negative inhibitors of the full-length c-Myc 1 and 2 proteins. The synthesis of Δ-c-Myc proteins is also regulated during cell growth and is repressed by methionine deprivation. Therefore, the synthesis of c-Myc 1 and Δ-c-Myc proteins are reciprocally regulated by methionine availability. We have also found some tumor cell lines which synthesize high levels of the Δ-c-Myc proteins. Taken together, our data suggest that c-Myc function is dependent on the levels of these different translational forms of c-Myc protein which are regulated by the nutritional status of the cell during growth.
Numerous reports have demonstrated a fundamental and diverse role for the myc gene in cellular events, including proliferation, differentiation and apoptosis (Cole 1986; Spencer and Groudine 1991; Askew et al. 1991; Evan et al. 1992). This is dramatically illustrated by the frequent occurrence of a variety of tumors in many species having alterations of myc genes and the transduction of c-myc sequences by retroviruses (Spencer and Groudine 1991). The diverse biological activity of myc is demonstrated by its ability to contribute to cellular proliferation (Spencer and Groudine 1991), inhibit terminal differentiation (Cole 1986), and promote apoptosis (Evan et al. 1992). Despite intensive study, however, the mechanism by which Myc proteins perform such diverse cellular roles is unknown (Luscher and Eisenman 1990).
A distinctive feature of the myc gene is that it encodes multiple N-terminally-distinct proteins. Alternative translational forms of the Myc protein exist for all species of c-Myc examined thus far (Hann and Eisenman 1984; Hann et al, 1988), as well as for N-Myc (Ramsay et al. 1986) and L-Myc proteins (Dosaka-Akita et al. 1991). The c-Myc 1 and 2 proteins have been found in all vertebrate species examined (Hann et al. 1988). In mammalian and avian cells, c-Myc 1 protein arises from an upstream non-AUG translational start site and thus contains an N-terminal extension of 14 amino acids compared to c-Myc 2 protein (Hann et al. 1988). Recently we have found that human, murine and avian cells also express smaller-sized c-Myc proteins to the full-length c-Myc 1 and 2 proteins (Spotts and Hann unpublished). These smaller-sized proteins, which we term Δ-c-Myc proteins, arise from translational initiation at a doublet of AUG codons downstream of the initiation sites for c-Myc 1 and 2 yielding proteins lacking the first 100 amino acids of c-Myc 2. Figure 1 diagrams the initiation of the different c-Myc proteins.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
J. Abastado, P.F. Miller, and A.G. Hinnebusch, A quantitative model for translational control of the GCN4 gene of Saccharomyces cerevisiae. The New Biologist 3: 511–524 (1991).
B., Amati, M.W. Brooks, N. Levy, T. Littlewood, G. Evan, and H Land, Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell 72: 233–245 (1993).
C. Amin, A. Wagner, and N. Hay, Sequence-specific transactivation by myc and repression by max. Mol.Biol.Cell. 13: 383–390 (1993).
D. Askew, R. Ashmun, B. Simmons, and J. Cleveland, Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and apoptosis. Oncogene 6: 1915–1922 (1991).
D.E. Ayer, L. Kretzner, and R.N. Eisenman, Mad: A heterodimeric partner for Max that antagonizes myc transcriptional activity. Cell 72: 211–222 (1993).
H.L. Beckmann, L.K. Su, and T. Kadesch, TFE3: Ahelix-loop-helix protein that activates transcription through the immunoglobulin enhancer 43 motif. Genes and Dey. 4: 167–179 (1990).
J. Bigler, W. Hokanson, and R.N. Eisenman, Thyroid hormone receptor transcriptional activity is potentially autoregulated by truncated forms of the receptor. Mol. Cell. Biol. 12: 2406–417 (1992).
T.K. Blackwell, L. Kretzner, E.M. Blackwood, R.N. Eisenman, and H. Weintraub, Sequence-specific DNA binding by the c-myc protein. Science 250: 1149–1151 (1990).
T.K. Blackwell, J. Huang, A. Ma, L. Kretzner, F. Alt, R.N. Eisenman, and H. Weintraub, Binding of Myc proteins to canonical and non-canonical DNA sequences. Mol. Cell. Biol. 13: 5216–5224 (1993).
E.M. Blackwood, and R.N. Eisenman, Max: A helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with myc. Science 251: 1211–1217 (1991).
E. Blackwood, T. Lugo, L. Kretzner, M. King, A. Street, O. Witte, and R.N. Eisenman, Functional analysis of the AUG- and CUG-initiated forms of the c-Myc protein. Mol. Biol. Cell, 5: 597–609 (1994)
Z. Cao, R. Umek, and S. McKnight, Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-LI cells. Genes Dey. 5: 1538–1552 (1991).
C.S. Carr, and P.A. Sharp, A helix-loop-helix protein related to immunoglobulin E box-binding proteins. Mol. Cell. Biol. 10: 4384–4388 (1990).
M.D. Cole, The myc oncogene:its role in transformation and differentiation. Ann. Rev. Genet. 20: 361–384 (1986).
P. Descombes, and U. Schibler, A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA. Cell 67: 569–579 (1991).
T.F. Donahue, A.M. Cigan, E.K. Pabich, and B.C. Valavicius, Mutations at a Zn(II) finger motif in the yeast eIF-2f3 gene alter ribosomal start-site selection during the scanning process. Cell 54: 621–632 (1988).
H. Dosaka-Akita, R.K. Rosenberg, J.D. Minna, and M.J. Birrer, A complex pattern of translational initiation and phosphorylation in L-Myc proteins. Oncogene 6: 371–378 (1991).
G. Evan, A.H. Wyllie, C. Gilbert, T. Littlewood, H. Land, M. Brooks, C. Waters, L. Penn, and D. Hancock, Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119–128 (1992).
N.S. Foulkes, and P. Sassone-Corsi, More is better: activators and repressors from the same gene. Cell 68: 411–414 (1992).
S.O. Freytag, and T.J. Geddes, Reciprocal regulation of adipogenesis by myc and C/EBPa. Science 256: 379–382 (1992).
P.D. Gregor, M. Sawadogo, and R.G. Roeder, The adenovirus major late transcription factor USF is a member of the helix-loop-helix group of regulatory and binds to DNA as a dimer. Genes and Dey. 4: 1730–1740 (1990).
W. Gu, K. Cechova, V. Tassi, and R. Dalla-Favera, Opposite regulation of gene transcription and cell proliferation by c-Myc and Max. Proc. Natl. Acad. Sci. 90: 2935–2939 (1993).
W. Gu, K. Bhatia, I. Magrath, C. Dang, and R. Dalla-Favera, Binding and suppression of the Myc transcriptional activation domain by p107. Science 264: 251–254 (1994).
S.R. Hann, M. Dixit, R. Sears, and L. Sealy, The alternatively-initiated c-Myc proteins differentially regulate transcription through a noncanonical DNA binding site. Genes and Dey. 8: 2441–2452 (1994).
S.R. Hann, and R.N. Eisenman, Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells. Mol. Cell. Biol. 4: 2486–2497 (1984).
S.R. Hann, M.W. King, D.L. Bentley, C.W. Anderson, and R.N. Eisenman, A non-AUG translational initiation in c-myc exon I generates an N-terminally distinct protein whose synthesis is disrupted in Burkitt’s lymphomas. Cell 34: 185–195 (1988).
S.R. Hann, K. Sloan-Brown, and G. Spotts, Translational activation of the non-AUG-initiated c-myc I protein at high cell densities due to methionine deprivation. Genes and Dey. 6: 1229–1240 (1992).
G. Hateboer, H. Timmers, A. Rustgi, M. Billaud, L. Van ‘T Veer, and R. Bernards, TATA-binding protein and the retinoblastoma gene product bind to overlapping epitopes on c-Myc and adenovirus E la protein. Proc. Natl. Acad. Sci. 90: 8489–8493 (1993).
J.W.B Hershey, Translational control in mammalian cells. Ann. Rev. Biochem. 60: 717–755 (1991).
Y.F. Hu, B. Luscher, A. Admon, N. Mermod, and R. Tjian, Transcription factor AP-4 contains multiple dimerization domains that regulate dimer specificity. Genes and Dey. 4: 1741–1752 (1990).
G.J. Kato, J. Barrett, M. Villa-Garcia, and C.V. Dang, An amino-terminal c-myc domain required for neoplastic transformation activates transcription. Mol. Cell. Biol. 10: 5914–5920 (1990).
M. Kozak, Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell 44: 283–292 (1986).
M. Kozak, Context effects and inefficient initiation at non-AUG codons in eukaryotic cell-free translation systems. Mol. Cell. Biol. 9: 5073–5080 (1989).
M. Kozak, Regulation of translation in eukaryotic systems. Ann. Rev. Cell Biol. 8: 197–225 (1991).
L. Kretzner, E.M. Blackwood, and R.N. Eisenman, Myc and Max proteins possess distinct transcriptional activities. Nature 359: 426–429 (1992).
B. Lewin, Oncogenic conversion by regulatory changes in transcription factors. Cell 64: 303–312 (1991).
B. Luscher, and R.N. Eiseman New light on myc and myb. Part I. myc. Genes and Dey. 4: 2025–2035 (1990).
S. Maheswaran, H. Lee, and G. Sonenshein, Intracellular association of the protein product of the c-myc oncogene with the TATA-binding protein. Mol. Cell. Biol. 14: 1147–1152 (1994).
T.P. Makela, P.J. Koskinen, I. Vastrik, and K. Alitalo, Alternative forms of Max as enhancers or suppressors of Myc-Ras cotransformation. Science 256: 373–376 (1992).
D.S. Peabody, Translation initiation at non-AUG triplets in mammalian cells. J. Biol. Chem. 264: 5031–5035 (1989).
H. Persson, L. Hennighausen, R. Taub, W. DeGrado, and P. Leder, Antibodies to human c-myc gene product: evidence of an evolutionarily conserved protein induced during cell proliferation. Science 225: 687–693 (1984).
G.C. Prendergast, and E.B. Ziff, Methylation-sensitive sequence-specific DNA binding by the c-myc basic region. Science 251: 186–189 (1991).
M. Ramirez, R.C. Wek, and A.G. Hinnenbusch, Ribosome association of GCN2 protein kinase, a translational activator of the GCN4 gene of Saccharomyces cerevisiae. Mol. Cell. Biol. 11: 3027–3036 (1991).
G. Ramsay, L. Stanton, M. Schwab, and J.M. Bishop, The human proto-oncogene N-myc encodes nuclear proteins that bind DNA. Mol. Cell. Biol. 6: 4450–4457 (1986).
L.M. Resar, C. Dolde, J.F. Barrett, C.V. and Dang, B-Myc inhibits neoplastic transformation and transcriptional activation by c-Myc. Mol. Cell. Biol. 13: 1130–1136 (1993).
A. Roy, C. Carruthers, T. Gutjahr, and R.G. Roeder, Direct role for Myc in transcription initiation mediated by interactions with TFII-I. Nature 365: 359–361 (1993).
L. Sealy, and R. Chalkley, At least two nuclear proteins bind specifically to the Rous sarcoma virus long terminal repeat enhancer. Mol. Cell. Biol. 7: 787–798 (1987).
R.C. Sears, and L. Sealy, Characterization of nuclear proteins that bind the EFH enhancer sequence in the Rous sarcoma virus LTR. J. 1 iron. 66: 6338–6352 (1992).
A. Shrivastava, S. Saleque, G.V. Kalpana, S. Artandi, S.P. Goff, and K. Calame, Inhibition of transcriptional regulator Yin-Yang-1 association with c-Myc. Science 262: 24796–24804 (1993).
C.A. Spencer, and M. Groudine, Control of c-myc regulation in normal and neoplastic cells. Adv. Cancer Res. 56: 1–48 (1991).
J. Stone, T. DeLange, G. Ramsay, E. Jakobovits, J.M. Bishop, H. Varmus, and W. Lee, Definition of regions of human c-myc that are involved in transformation and nuclear localization. Mol. Cell. Biol. 7: 1967–1709 (1987).
D. Tzamarias, I. Roussou, and G. Thireos, Coupling of GCN4 mRNA translational activation with decreased rates of polypeptide chain initiation. Cell 57: 947–954 (1989).
R.M. Umek, A.D. Friedman, and S.L. McKnight, CCAAT/enhancer binding protein: a component of a differentiation switch. Science 251: 288–292 (1991).
R.C. Wek, B.M. Jackson, and A.G. Hinnebusch, Juxtaposition of domains homologous to protein kinases and histidyl-tRNA synthetases in GCN2 protein suggests a mechanism for coupling GCN4 expression to amino acid availability. Proc. Natl. Acad. Sci. USA 86: 4579–4583 (1989).
N.P. Williams, A.G. Hinnebusch, and T.F. Donahue, Mutations in the structural genes for eukaryotic initiation factors 2a and 2ß of Saccharomyces cerevisiae disrupt translational control of GCN4 mRNA. Proc. Natl. Acad. Sci. USA 86: 7515–751 (1989).
A.S. Zervos, J. Gyuris, and R. Brent, Mxi1, a protein that specifically interacts with Max to bind Myc/Max recognition sites. Cell 72: 223–232 (1993).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Hann, S.R. (1995). Methionine Deprivation Regulates the Translation of Functionally-Distinct c-Myc Proteins. In: Diet and Cancer. Advances in Experimental Medicine and Biology, vol 354. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0949-7_10
Download citation
DOI: https://doi.org/10.1007/978-1-4899-0949-7_10
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-0951-0
Online ISBN: 978-1-4899-0949-7
eBook Packages: Springer Book Archive